I-Corps: Fluid Volume Responsiveness Monitor to Support the Care of Septic Patients

败血症是一种对感染的全身炎症反应，每年影响超过100万美国人，导致约25.8万人死亡。它是美国医院四大最昂贵的疾病之一，每年花费医疗系统超过200亿美元。脓毒症是用广谱抗生素治疗的。然而，在治疗过程中，心脏将血液输送到全身的能力会降低，从而导致器官衰竭。因此，静脉输液用于维持每次心脏跳动所泵出的血容量。虽然最初提供液体是必不可少的，但当循环系统无法对额外的液体做出反应时，它可能是有害的。研究表明，早期识别患者何时不再需要补液可以降低死亡风险，加快康复速度，减少使用呼吸机的时间。因此，知道何时停止给病人输液并改变策略以支持血液流动是至关重要的。目前进行这些测量的方法是不准确的，侵入性的，并且不利于脓毒症患者的护理。提出的技术克服了现有方法的局限性，可以提供对患者的持续评估。S流体反应性。该系统将使急诊科和重症监护病房的提供者能够收集液体反应数据，医生可以使用这些数据来优化患者护理。该团队设想，优化败血症护理将缩短恢复时间，减少与败血症相关的死亡人数。此外，拟议的系统将帮助医院实现遵守最近制定的败血症质量法规。该团队计划开发一种生理测量系统，以准确评估液体体积的反应性。所提出的技术可以通过多种方式整合到产品中。例如，可以开发一种自动化的、低姿态的基于超声波的智能传感器贴片。或者，该技术可以与现有超声机的软件集成，甚至可以实现一个软件包，集成来自各种医院信息源的数据。为了确定理想的解决方案，团队打算了解用户-购买者-付款人的交互，以及监管和报销情况。I-Corps项目将帮助该团队实现这一目标，增强其为我们的技术开发一个合理的价值主张、商业模式和商业化战略的能力。通过密集的客户发现过程，团队将发现包装我们的技术以满足客户需求的最佳方式。

Sepsis is a whole-body inflammatory response to an infection, which affects more than 1 million Americans per year and results in about 258,000 deaths. It is one of the top four most costly conditions occurring in US hospitals, costing the healthcare system more than $20 B annually. Sepsis is treated using broad spectrum antibiotics. However, during treatment the heart's ability to pump blood throughout the body is reduced which can lead to organ failure. Therefore, intravenous fluids are used to maintain the volume of blood pumped per heart beat. While initially, providing fluids is essential, it can be harmful when the circulatory system cannot respond to additional fluid. Studies have shown that the early identification of when patients no longer need fluids can reduce the risk of death, speed recovery and decrease days spent on a ventilator. It is therefore critical to know when to stop giving the patient fluids and switch strategies to support blood flow. Current methods to perform these measurements, are inaccurate, invasive, and are not conducive to the care of septic patients. The proposed technology overcomes the limitations of current methods and can provide the continuous assessment of a patient?s fluid responsiveness. This system will empower emergency department and intensive care unit providers to collect fluid responsiveness data, which physicians can use to optimize patient care. The team envisions that optimizing sepsis care would decrease recovery times and reduce the number of deaths associated with sepsis. In addition, the proposed system will help hospitals achieve compliance with recently instituted sepsis quality regulations.The team plans to develop a physiologic measurement system for the accurate assessment of fluid volume responsiveness. The proposed technology could be incorporated into a product in numerous ways. For example, an automated, a low-profile ultrasound-based smart sensor patch could be developed. Alternately, the technology could be integrated with the software of existing ultrasound machines, or even a software package could be realized that integrates data from various hospital-based information sources. To determine the ideal solution the team intends to understand the user-buyer-payer interaction, as well as the regulatory and reimbursement landscape. The I-Corps program will help this team achieve this goal by enhancing its ability to develop a sound value proposition, business model, and commercialization strategy for our technology. Though an intensive customer discovery process the team will discover the best way to package our technology to meet the needs of customers.